CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
1.690
-0.140 (-7.65%)
At close: Nov 13, 2026, 4:00 PM EST
1.673
-0.017 (-1.02%)
After-hours: Nov 13, 2026, 7:58 PM EST
CervoMed Revenue
CervoMed had revenue of $8.73K in the twelve months ending September 30, 2026, down -99.86% year-over-year. In the year 2025, CervoMed had annual revenue of $4.01M, down -58.86%. That makes CervoMed the 47,304th largest company in the world by revenue and 7,179th in the United States.
Revenue (ttm)
$8.73K
Revenue Growth
-99.86%
P/S Ratio
2,912.67
Revenue / Employee
$582
Employees
15
Market Cap
25.57M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.01M | -5.73M | -58.86% |
| Dec 31, 2024 | 9.74M | 2.59M | 36.29% |
| Dec 31, 2023 | 7.14M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 71.67K | -302.88K | -80.87% |
| Dec 31, 2012 | 374.54K | -195.93K | -34.35% |
| Dec 31, 2011 | 570.48K | 530.29K | 1,319.48% |
| Dec 31, 2010 | 40.19K | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | 40.19K | -268.57K | -86.98% |
| Dec 31, 2007 | 308.76K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 34.59M |
| Celularity | 18.67M |
| Immutep | 13.79M |
| Evaxion | 7.49M |
| Metagenomi Therapeutics | 7.09M |
| BeyondSpring | 1.88M |
| ABVC BioPharma | 797.92K |
CRVO News
- 3 days ago - CervoMed price target lowered to $6 from $7 at Roth Capital - TheFly
- 4 days ago - CervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 7 days ago - CervoMed Quarterly report: Q3 2026 - Filings
- 7 days ago - CervoMed Earnings release: Q3 2026 - Filings
- 15 days ago - CervoMed announces publication of two articles supporting neflamapimod - TheFly
- 15 days ago - CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB) - GlobeNewsWire
- 4 weeks ago - CervoMed presents initial data from neflamapimod trial - TheFly
- 6 weeks ago - CervoMed neflamapimod update removes key overhang, says Jones - TheFly